 Connection
Whitney Goldner to Biomarkers, Tumor
This is a "connection" page, showing publications Whitney Goldner has written about Biomarkers, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.288 |
|
|
|
-
Kotwal A, Vance K, Hajric K, Yuil-Valdes A, Swanson B, Martinez Duarte E, Shats O, Hollingsworth M, Band H, Goldner W. Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer. Thyroid. 2024 08; 34(8):999-1006.
Score: 0.126
-
Kotwal A, Simpson R, Whiteman N, Swanson B, Yuil-Valdes A, Fitch M, Nguyen J, Elhag S, Shats O, Goldner W, Bennett R. Relaxin-2 is a novel biomarker for differentiated thyroid carcinoma in humans. Biochem Pharmacol. 2024 07; 225:116323.
Score: 0.125
-
Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440.
Score: 0.021
-
Zahid M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL. Unbalanced estrogen metabolism in thyroid cancer. Int J Cancer. 2013 Dec 01; 133(11):2642-9.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|